RJA
NTLA icon

Raymond James & Associates’s Intellia Therapeutics NTLA Stock Holding History

Raymond James & Associates’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.66M Sell
178,254
-29,041
-14% -$670K ﹤0.01% 1866
2024
Q2 		$4.64M Buy
207,295
+52,671
+34% +$1.25M ﹤0.01% 1630
2024
Q1 		$4.25M Buy
154,624
+20,253
+15% +$563K ﹤0.01% 1701
2023
Q4 		$4.1M Buy
134,371
+29,997
+29% +$862K ﹤0.01% 1666
2023
Q3 		$3.3M Buy
104,374
+34,458
+49% +$1.34M ﹤0.01% 1717
2023
Q2 		$2.85M Buy
69,916
+16,998
+32% +$689K ﹤0.01% 1844
2023
Q1 		$1.97M Buy
52,918
+31,818
+151% +$1.25M ﹤0.01% 2046
2022
Q4 		$736K Buy
21,100
+2,769
+15% +$132K ﹤0.01% 2619
2022
Q3 		$1.03M Buy
18,331
+4,717
+35% +$293K ﹤0.01% 2374
2022
Q2 		$705K Sell
13,614
-486
-3% -$24.7K ﹤0.01% 2681
2022
Q1 		$1.02M Sell
14,100
-3,134
-18% -$266K ﹤0.01% 2573
2021
Q4 		$2.04M Sell
17,234
-10,952
-39% -$1.37M ﹤0.01% 2162
2021
Q3 		$3.78M Buy
28,186
+3,592
+15% +$544K ﹤0.01% 1687
2021
Q2 		$3.98M Sell
24,594
-1,633
-6% -$127K ﹤0.01% 1637
2021
Q1 		$2.1M Buy
26,227
+7,880
+43% +$529K ﹤0.01% 1974
2020
Q4 		$998K Buy
18,347
+5,217
+40% +$189K ﹤0.01% 2349
2020
Q3 		$261K Sell
13,130
-4,354
-25% -$90.8K ﹤0.01% 3041
2020
Q2 		$368K Sell
17,484
-1,130
-6% -$19.2K ﹤0.01% 2804
2020
Q1 		$228K Buy
18,614
+350
+2% +$4.71K ﹤0.01% 2948
2019
Q4 		$268K Buy
+18,264
New +$254K ﹤0.01% 3151
2018
Q3 		– Sell
-8,688
Closed -$238K – 3691
2018
Q2 		$238K Sell
8,688
-3,839
-31% -$93K ﹤0.01% 3159
2018
Q1 		$264K Buy
+12,527
New +$308K ﹤0.01% 2968

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's NTLA Position: Q3 2024 in Review

Raymond James & Associates reduced its Intellia Therapeutics (NTLA) stake by 14% in Q3 2024, selling an estimated $670K and leaving 178,254 shares worth $3.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1866.

Raymond James & Associates first reported a position in NTLA in Q1 2018 and has held it in 22 quarters since. The position peaked at $4.64M in Q2 2024. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Raymond James & Associates held 178,254 shares of Intellia Therapeutics worth $3.66M as of Q3 2024.
  • Raymond James & Associates sold 29,041 Intellia Therapeutics shares in Q3 2024, an estimated $670K.
  • Intellia Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1866 holding.
  • Raymond James & Associates first reported a position in Intellia Therapeutics in Q1 2018 and has held it in 22 quarters since.
  • Raymond James & Associates's Intellia Therapeutics position peaked at $4.64M in Q2 2024.
  • 283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.